Skip to content

Price / earnings at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
39.3×-4.6×
TFX
TeleflexTFX
27.7×-9.9×
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
52×+12.2×
IAR
Integra LifeSciencesIART
95.8×+70.8×
Merit Medical Systems logo
Merit Medical SystemsMMSI
29.4×-21.5×
PDE
Pro-Dex, Inc.PDEX
13.1×-4.1×

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Gross profit$5.3M-4.6%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Cash & equivalents$87.4M+4.9%
Total debt$210.0K
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity
Current ratio28.6×+6.3×

Where this comes from

Calculated from Utah Medical Products’s reported figures.

Based on the most recent quarter.

The official record: Utah Medical Products’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's price / earnings?
Utah Medical Products (UTMD) reported price / earnings of 18.2× in Q1 2026.
How has Utah Medical Products's price / earnings changed year-over-year?
Utah Medical Products's price / earnings increased by 28.2% year-over-year, from 14.2× to 18.2×.
What is the long-term trend for Utah Medical Products's price / earnings?
Over 5 years (2020 to 2025), Utah Medical Products's price / earnings has grown at a -11.0% compound annual growth rate (CAGR), from 28.5× to 15.9×.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.